Marco Proietti (Institute of Cardiovascular Sciences, University of Birmingham, Birmingham) discusses the SPORTIF Trials and their aim to investigate and compare ximelagatran, the first non-vitamin K antagonist oral anticoagulant, with warfarin in patients with atrial fibrillation. The trial was stopped and the drug never commercialised due to adverse liver events, however there is still a lot of data from the randomised controlled trials in the warfarin arm. Dr Proietti discusses the potential for additional and subgroup analysis performed on this data, particularly his work to identify the potential for bleeding risk and adverse bleeding events in patients with atrial fibrillation and bad anticoagulation control who regularly take a number of non-steroidal anti-inflammatory drugs (NSAIDs).
Filmed at EHRA 2018, Barcelona.
1. What was the background and rationale behind your study? 0:07
2. What were the results you presented at this meeting? 1:21
3. What are the next steps in this area of research over the coming years? 2:49
Share this Video
Related Videos In Atrial Fibrillation
Anthony Tang, ACC 2021: Findings from the RAFT-AF Trial
It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021. Abstract Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus […]
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!